Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HF 4034Session 2025-2026

Right to Try Act modified for individualized investigational treatments.

Introduction March 5, 2026

Underlined text would be added to current law. Struck-through text would be removed.

Skip to main content Skip to footer Minnesota Legislature Advanced Search Search Legislature Search Menu
  • House
  • Minnesota House of Representatives House Members and Staff House Members Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Committee Deadlines Offices Chief Clerk Fiscal Analysis House Research Public Information Sergeant-at-Arms Caucuses - DFL/GOP Other Information House Journal House Rules Joint Rules Educational Programs Pronunciation Guide Address Spreadsheet
  • Senate
  • Minnesota Senate Senators and Staff Senators Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Committee Deadlines Offices Secretary of the Senate Senate Counsel, Research & Fiscal Analysis Caucuses - DFL/GOP Other Information Senate Journal Senate Rules Joint Rules Educational Programs Address Labels Subscriptions
  • Joint
  • Joint Department, Offices, and Commissions Joint Legislative Offices Legislative Budget Office Legislative Coordinating Commission (LCC) Legislative Reference Library Office of the Legislative Auditor Office of the Revisor of Statutes Commissions Legislative-Citizen Commission on MN Resources Legislative Commission on Pensions & Retirement Lessard-Sams Outdoor Heritage Council More... More Information Joint Offices Directory Joint Offices Staff Accessibility Legacy Amendment
  • Schedules
  • Schedules, Calendars, and Legislative Business House House Schedules Order of Business Calendar for the Day Supplemental Calendar for the Day Fiscal Calendar Senate Senate Schedules Order of Business Senate Calendar General Orders of the Day Joint Combined Upcoming Meetings Broadcast TV Schedule Committee Deadlines
  • Committees
  • Legislative Committees House Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Senate Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Joint Joint Committees & Task Forces Committee Deadlines Bills In Conference Committee Side by Side Comparisons
  • Bills
  • Bills House Bill Search & Status (House) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Senate Bill Search & Status (Senate) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Joint Bill Search & Status MyBills Side by Side Comparisons Bills In Conference Committee Vetoes Current Session Laws
  • Law
  • Statutes, Laws, and Rules Statutes Keyword Search Current Statutes Statutes by Topic (Index) Statutes Archive Session Laws Keyword Search Current Session Laws Session Laws by Topic (Index) Session Laws Archive Session Laws Changed (Table 1) Statutes Changed (Table 2) Administrative Rules Keyword Search Current Rules Rules by Topic (Index) Rules Archive Minnesota Rule Status State Register Other Legal Materials Minnesota Constitution State Constitutional Amendments Court Rules
  • Multimedia
  • Multimedia - Audio, Video, Broadcast TV, News, & Photos House Live Video Audio Webcast Schedule Audio & Video Archives Session Daily Photos Senate Live Video Audio Webcast Schedule Audio & Video Archives Senate Media Services Photos Joint Combined Media Page Legislative Media Archive Broadcast TV Schedule Commission Audio/Video
  • Publications
  • Legislative Research, Reports & Information Office Research & Reports House Fiscal Analysis House Research Senate Counsel Publications Legislative Auditor Revisor Publications Legislative Reference Library News House Session Daily Senate Media Services Senate Information Legislators Roster Member Guide Legislative History Legislative History Guide Legislators Past & Present House Journal Senate Journal Legislative Time Capsule Vetoes Notable Documents Fiscal Review Minnesota Issues Guides New Laws Books & reports
Search Legislature Search Office of the Revisor of Statutes

Office of the Revisor of Statutes

Revisor Menu
  • Retrieve by number Document type Statutes Laws Rules Bills GO
  • Statutes
  • Laws
  • Rules
  • Court Rules
  • Constitution
  • Revisor's Office Revisor Intranet Attorney Drafting Areas Staff Directory Office Duties Publications Educational Seminars Employment Openings Order Publications
  • Search Law by Keyword
  • Bills
  • 94th Legislature (2025 - 2026)
  • HF4034
  • Introduction

HF 4034

Introduction - 94th Legislature (2025 - 2026)

Posted on 03/18/2026 11:48 a.m.

KEY: stricken = removed, old language. underscored = added, new language. Version List HF4034 Authors and Status PDF Rtf

Bill Text Versions

Engrossments
Introduction PDF Posted on 03/05/2026
Jump to page/line # Line numbers 1.1 1.2 1.3 1.4
1.5 1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25

A bill for an act
relating to health care; modifying the Right to Try Act for individualized
investigational treatments; amending Minnesota Statutes 2024, section 151.375.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2024, section 151.375, is amended to read:


151.375 INVESTIGATIONAL DRUG USE.

Subdivision 1.

Title; citation.

This section may be cited as the "Right to Try Actnew text begin 2.0new text end ."

Subd. 2.

Definitions.

(a) For the purposes of this section, the following terms have the
meanings given them.

(b) "Eligible patient" means a patient who meets the requirements in subdivision 3.

(c) "new text begin Individualized new text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end " means
a drug, biological product, or device that deleted text begin has successfully completed phase 1 of a clinical
trial, but has not been approved for general use by the federal Food and Drug Administration
(FDA), and is currently under investigation in a FDA clinical trialdeleted text end new text begin is unique to and produced
exclusively for use by an individual patient based on the patient's genetic profile and includes
but is not limited to individualized gene therapy antisense oligonucleotides and individualized
neoantigen vaccines
new text end .

deleted text begin (d) "Terminal illness" means a condition or illness which, to a reasonable degree of
medical probability, is not considered reversible and even with the administration of current
FDA-approved and available treatments and the administration of life-sustaining procedures
will soon result in death.
deleted text end

new text begin (d) "Life-threatening" has the meaning given in Code of Federal Regulations, title 21,
section 312.81(a).
new text end

new text begin (e) "Severely debilitating" has the meaning given in Code of Federal Regulations, title
21, section 312.81(b).
new text end

Subd. 3.

Eligibility.

In order for a patient to access an new text begin individualized new text end investigational
deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end under this section, a physician must document
in writing that the patient:

(1) has a deleted text begin terminal illnessdeleted text end new text begin life-threatening or severely debilitating illnessnew text end ;

(2) has, in consultation with a physician, considered all other treatment options currently
approved by the FDA;

(3) has deleted text begin been given a prescription or recommendation by a physician for an investigational
drug, biological product, or devicedeleted text end new text begin received a recommendation from the patient's physician
for an individualized investigational treatment based on analysis of the patient's genomic
sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene
products, or metabolites
new text end ; and

(4) has given new text begin written new text end informed consentdeleted text begin , in writing,deleted text end for the use of the new text begin individualized
new text end investigational deleted text begin drug, biological product, or device,deleted text end new text begin treatment new text end ornew text begin ,new text end if the patient is under the
age of 18deleted text begin ,deleted text end or lacks the mental capacity to provide informed consent, a parent or legal guardian
has given new text begin written new text end informed consentdeleted text begin , in writing,deleted text end on behalf of the patient.

Subd. 4.

Availability.

(a) A manufacturer of an new text begin individualized new text end investigational deleted text begin drug,
biological product, or devicedeleted text end new text begin treatmentnew text end has the option of making its new text begin individualized
new text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end available to eligible patients
under this section.

(b) Nothing in this section shall be construed to require a manufacturer to make an
new text begin individualized new text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end available.

Subd. 5.

Costs.

(a) A manufacturer may provide an new text begin individualized new text end investigational deleted text begin drug,
biological product, or devicedeleted text end new text begin treatmentnew text end without receiving compensation.

(b) A manufacturer may require an eligible patient to pay the costs associated with
manufacturing thenew text begin individualizednew text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end .

new text begin (c) If a patient dies while being treated with an individualized investigational treatment
under this section, the manufacturer must not collect the costs associated with manufacturing
the individualized investigational treatment from the patient's heirs or any individuals with
the right to inherit under the patient's estate.
new text end

Subd. 6.

Professional licensing.

No health care provider shall be subject to a civil penalty
or disciplinary action by any business, occupational, or professional licensing board, solely
for providing a prescription or recommendation, or providing treatment to an eligible patient
in accordance with this section. Nothing in this section affects a professional licensing board
from taking action in response to violations of any other section of law.

Subd. 7.

Coverage.

Nothing in this section shall be construed to require that the costs
associated with an new text begin individualized new text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end
be covered under private health coverage, a state public health care program, the state
employee group insurance program, or a program administered by a state or local government
agency that provides health care services to inmates residing in a state or county correctional
facility.

Subd. 8.

Liability.

Nothing in this section shall create a separate private cause of action
against any health care provider or entity involved in the care of an eligible patient using
an new text begin individualized new text end investigational deleted text begin drug, biological product, or device,deleted text end new text begin treatmentnew text end for any harm
done to the patient resulting from the new text begin individualized new text end investigational deleted text begin drug, biological product,
or devicedeleted text end new text begin treatmentnew text end , so long as the health care provider or entity is complying with the
requirements of this section.

Subd. 9.

Exception.

This section does not apply to a person committed to the custody
of the commissioner of corrections unless the department's medical director approves the
new text begin individualized new text end investigational deleted text begin drug, biological product, or devicedeleted text end new text begin treatmentnew text end .

Subd. 10.

Severability.

If any provision of this section or its application to any person
or circumstances is held to be invalid, the invalidity of the provision shall not affect any
other provision of this section. The provisions of this section are severable.

About the Legislature
  • Historical Information
  • Employment/Internships
  • Visiting the Capitol
  • Accessibility
  • Frequently Asked Questions
Contact Your Legislator
  • Who Represents Me?
  • House Members
  • Senators
General Contact
  • Contact a legislative librarian:
  • (651) 296-8338 or Email
  • Phone Numbers
  • Submit website comments
Get Connected
  • House News
  • Senate News
  • MyBills
  • Email Updates & RSS Feeds
Minnesota Office of the Revisor of Statutes, Centennial Office Building, 3rd Floor, 658 Cedar Street, St. Paul, MN 55155

Official text from the Minnesota Legislature. Formatting has been adapted for reading on Ratifi.